In highly selected patients with locally advanced pancreatic cancer, surgical resection after neoadjuvant therapy is feasible and associated with longer overall survival, researchers report.

News

Multiple preoperative indicators may be used as prognostic markers for patients with operable pancreatic ductal adenocarcinoma, according to a new study.

Read More

By Reuters Staff

NEW YORK (Reuters Health) – The pancreatic cancer resectability criteria advocated by the National Comprehensive Cancer Network (NCCN) may be more complicated than necessary, Japanese researchers say.

Read More

By David Douglas

NEW YORK (Reuters Health) - In concert with the peptide iRGD, nanoparticles with hollow silica cores can enhance the delivery of irinotecan to a murine model of pancreatic ductal adenocarcinoma, according to California-based researchers.

Read More

The American Society of Clinical Oncology (ASCO) has updated their recommendations for adjuvant treatment of surgically resected pancreatic cancer, published in the Journal of Clinical Oncology (published online April 11, 2017; doi:10.1200/JCO.2017.72.4948).

Read More

Subscribe to Pancreatic Cancer